[keihanna]

This Nature’s Article.

https://www.nature.com/articles/d41586-018-07407-9
Reprogrammed’ stem cells implanted into patient with Parkinson’s disease

[keihanna]

Tha is true. For the patients the more companies the more results I hope.

World’s first commercial iPS cell-making plant opens
The new center will use iPS cells created by Kyoto University’s Center for iPS Cell Research and Application (CiRA) and other institutes not only to proliferate them, but to convert them into retina and other cells. These iPS-derived cells can then be shipped to medical centers for treatment use.

According to Sumitomo Dainippon Pharma officials, a large amount of cells enough to treat hundreds of patients can be produced annually in each zone of the facility.

Working with the Riken research institute, CiRA, Keio University and other institutions, Sumitomo Dainippon Pharma is developing iPS cell-based products to treat age-related macular degeneration, retinitis pigmentosa and other eye diseases as well as Parkinson’s disease and spinal cord injuries.

The company intends to make regenerative medicine one of its future core businesses and is looking to boost its sales in the field to 200 billion yen ($1.8 billion) by 2030.

[keihanna]

Actually https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_companies_by_revenue

Actually Takeda is pretty big top 20 th ine world. about same size of Bristol-Myers and has quite a big entity in the US as well.

I am sure big Amrican comanies are looking at this.

Example

Ono Japanese small pharmaceutical company started to sell cancer cure revolutionary medicine. invented by Mr. Honjo who got Nobel prize this year. and Bristol Myers got interested in the medicine and invested heavyly now Merck is paying a loyalty fee to Ono.

.

[keihanna]

The Center for iPS Cell Research and Application (CiRA), Kyoto University, has announced the construction of a master cell bank (MCB)1 from the CiRA iPS Cell Stock for Regenerative Medicine2 with Takeda Pharmaceutical Company Limited (Takeda).

The MCB construction is part of the Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), a large scale collaboration between CiRA and Takeda that aims to apply iPS cell technologies for treatment of multiple diseases.

The CiRA iPS Cell Stock for Regenerative Medicine (The iPS Cell Stock Project) is preparing and storing multiple iPS cell lines for clinical application. Each line is made by reprogramming cells from healthy donors who are human leukocyte antigen (HLA) homozygous. The use of HLA homozygous donors expands the number of people who can receive the cells in a therapy without a severe immune reaction.